Completed

Effectiveness of Combination Therapy of Microneedling and Minoxidil in Androgenetic Alopecia of Indonesian Men

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Minoxidil 5% Topical Solution

+ microneedling

DrugDevice
Who is being recruted

Alopecia+4

+ Hair Diseases

+ Hypotrichosis

From 18 to 59 Years
+10 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 3
Interventional
Study Start: June 2023
See protocol details

Summary

Principal SponsorIndonesia University
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: June 1, 2023

Actual date on which the first participant was enrolled.

This clinical trial is focused on finding a better treatment for hair loss, specifically in Indonesian men who have androgenetic alopecia, a common form of hair loss. The study is looking at whether a combination of two treatments, microneedling and minoxidil, is more effective than just using minoxidil alone. Hair loss can affect self-esteem and confidence, so finding a more effective treatment could greatly improve the quality of life for those affected. The trial aims to see if the combination therapy leads to more hair growth and thicker hair than using only minoxidil. Participants in this trial are divided into two groups. One group uses only minoxidil, which is a topical medication applied directly to the scalp. The other group receives both microneedling, a procedure that uses tiny needles to stimulate the scalp, and minoxidil. Researchers will compare the results between these groups by measuring hair density, which refers to the number of hairs in a given area of the scalp, and hair diameter, which indicates the thickness of individual hairs. The study is designed to determine which treatment approach has the best outcomes in improving hair growth and thickness.

Official TitleEffectiveness of Combination Therapy of Microneedling and Minoxidil in Androgenetic Alopecia of Indonesian Men
NCT05989165
Principal SponsorIndonesia University
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

36 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Male

Biological sex of participants that are eligible to enroll.

From 18 to 59 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

AlopeciaHair DiseasesHypotrichosisSkin DiseasesPathological Conditions, Signs and SymptomsSkin and Connective Tissue DiseasesPathological Conditions, Anatomical

Criteria

5 inclusion criteria required to participate
Male

Indonesian

Age 18-59 years

Diagnosis of androgenetic alopecia

Show More Criteria

5 exclusion criteria prevent from participating
Use of minoxidil or finasteride topical 1 month prior

Use of minoxidil or finasteride oral 1 month prior

Skin infection in the treatment area

Cosmetic procedures for the treatment of alopecia androgenetic such as platelet rich plasma, laser therapy,or microneedling 3 months prior

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
Patients will receive a combination therapy of microneedling and minoxidil 5%. Minoxidil 5%, will be given twice a day for a total duration of 12 weeks. The microneedling treatment will be given every 4 weeks (week 0, week 4, week 8)for a total duration of 12 weeks.

Group II

Experimental
Patients will receive minoxidil 5%, twice a day, for a total duration of 12 weeks.

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Cipto Mangungkusumo Hospital

Jakarta, IndonesiaOpen Cipto Mangungkusumo Hospital in Google Maps
CompletedOne Study Center